Exemplify Biopharma, Inc, 3000 Eastpark Blvd, Ste 500, Cranbury, NJ 08512, US

EmphyCorp Inc. is a private biotech company based in Flemington, New Jersey, specializing in the development of non-steroidal nasal spray drugs for the treatment of respiratory diseases, including pulmonary fibrosis, cystic fibrosis, COPD, asthma, and flu. With a focus on improving patients' quality of life, EmphyCorp has completed 19 human FDA clinical studies, demonstrating the safety and efficacy of their products, which have been used by over 3.5 million patients globally. Their innovative nasal spray, N115, has shown significant reductions in inflammation, viral numbers, and symptoms associated with COVID-19, making EmphyCorp a leading player in the field of respiratory treatments. Driven by a passion for creating safer and more effective solutions, EmphyCorp's drug pipeline includes ongoing research and development for respiratory diseases, COVID-19, long COVID, and flu. With a strong commitment to scientific rigor, their clinical trials have been published in prestigious peer-reviewed journals, such as the European Journal of Respiratory Medicine. As a pioneer in the industry, EmphyCorp holds multiple patents for their nasal spray drugs, including a recent patent for a hypoxemia drug. With a focus on innovation and patient well-being, EmphyCorp continues to make significant strides in the field of respiratory treatments.Generated from the website

Belrose Pharma Inc

Quantex Laboratories Inc

Crystal Pharmatech